Derlin-1 Inhibitors
Derlin-1 inhibitors belong to a class of chemical compounds that specifically target the protein Derlin-1, an integral component of the endoplasmic reticulum-associated degradation (ERAD) pathway. The ERAD pathway plays a crucial role in maintaining cellular homeostasis by identifying and disposing of misfolded or unfolded proteins within the endoplasmic reticulum (ER). Derlin-1, situated in the ER membrane, serves as an essential factor in the recognition and translocation of aberrant proteins from the ER to the cytoplasm for subsequent degradation.
Inhibitors designed to modulate Derlin-1 activity are of particular interest due to their potential impact on cellular protein quality control mechanisms. Derlin-1 inhibitors lies in the need to better understand and manipulate the ERAD pathway for various research purposes. By selectively obstructing Derlin-1 function, these inhibitors offer a valuable tool for investigating the intricate processes involved in protein quality control within the cell. Researchers aim to uncover the precise molecular mechanisms underlying Derlin-1's role in ERAD and explore how its inhibition might affect cellular responses to protein misfolding.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is another proteasome inhibitor. By blocking the proteasome, it indirectly influences the function of Derlin-1, which is part of the endoplasmic reticulum-associated degradation (ERAD) system, a process linked to the proteasome. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific and potent inhibitor of the proteasome. Its activity can indirectly affect Derlin-1 by affecting the ERAD pathway. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a highly potent, selective, and irreversible proteasome inhibitor. It can indirectly inhibit Derlin-1 activity by affecting the proteasome and thus the ERAD pathway. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a proteasome inhibitor that can influence the ERAD pathway and indirectly inhibit Derlin-1 functioning. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
Celastrol is a proteasome inhibitor that can indirectly inhibit Derlin-1 by affecting the ERAD pathway. | ||||||
Nelfinavir | 159989-64-7 | sc-507314 | 10 mg | $168.00 | ||
Nelfinavir is a protease inhibitor that can influence the ERAD pathway and indirectly inhibit Derlin-1. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a potent proteasome inhibitor that can indirectly inhibit Derlin-1 by interfering with the ERAD pathway. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is another proteasome inhibitor. It can indirectly inhibit Derlin-1 by influencing the ERAD pathway. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a proteasome inhibitor that can indirectly inhibit Derlin-1 by influencing the ERAD pathway. | ||||||